Processa Pharmaceuticals, Inc.
PCSA
$2.55
-$0.01-0.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.19% | 14.33% | 2.82% | 6.91% | -15.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.08% | 10.48% | 23.07% | 18.97% | 5.19% |
| Operating Income | -16.08% | -10.48% | -23.07% | -18.97% | -5.19% |
| Income Before Tax | -14.46% | -12.21% | -26.00% | -21.70% | -6.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.46% | -12.21% | -26.00% | -21.70% | -6.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.46% | -12.21% | -26.00% | -21.70% | -6.55% |
| EBIT | -16.08% | -10.48% | -23.07% | -18.97% | -5.19% |
| EBITDA | -16.07% | -10.48% | -23.06% | -21.32% | -8.93% |
| EPS Basic | 82.62% | 71.18% | 56.00% | 50.49% | 55.01% |
| Normalized Basic EPS | 82.62% | 71.18% | 56.00% | 50.49% | 55.01% |
| EPS Diluted | 82.62% | 71.18% | 56.00% | 50.49% | 55.01% |
| Normalized Diluted EPS | 82.62% | 71.18% | 56.00% | 50.49% | 55.01% |
| Average Basic Shares Outstanding | 954.19% | 651.42% | 288.52% | 193.65% | 133.48% |
| Average Diluted Shares Outstanding | 954.19% | 651.42% | 288.52% | 193.65% | 133.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |